Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

NCT01303315 is registered in ClinicalTrials.gov with MetaCure (USA), Inc. as lead sponsor.

NCT NCT01303315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01303315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy
Lead sponsor
MetaCure (USA), Inc.
Phase
Not applicable
Overall status
Terminated
Start date
January 31, 2011
Completion date
July 31, 2011
Enrollment
20 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2